Terumo Corporation · TSE:4543
Terumo — FY2016 Earnings Presentation
12 slides from Terumo's earnings presentation, May 10, 2017
Slide 1: Review on Performance in FY2016 and Mid- to Long-term Vision
Review on Performance in FY2016 and Mid- to Long-term Vision Terumo Corporation President and CEO Shinjiro Sato May 10, 2017
Slide 2: FY2016: Gear Shifting toward New Growth Strategy
FY2016: Gear Shifting toward New Growth Strategy Previous Mid- to Long-term Operating Sales FY16 Mid-term Growth Strategy income in BJPY in BJPY 800 Profitability Gear Accelerate 120 ■ Sales improvement shifting “Sustainable and Operating income Profitable Growth” (excl. amortization) 100 600 80 400
Slide 3: Review on Performance in FY2016
Review on Performance in FY2016 FY2016: Gear shifting toward next growth strategy Achieved target of "Roadmap to FY16“ in FY2015, a year ahead of schedule Secured a solid foothold in “Mid- to Long-term Growth Strategy” Outcome Sales expansion: M&As improved portfolio mix in Cardiac and Vas
Slide 4: Sales Expansion: M&As improved portfolio mix in Cardiac and Vascular Company
Sales Expansion: M&As improved portfolio mix in Cardiac and Vascular Company Business Acquisition Contribution Strategic Purpose Segment Neurovascular New Aneurysm Mid- to Introduce new technology as a (Jun) Embolization Device Long-term first mover to U.S. Gain new technology resources TIS Vasc
Slide 5: Profitability Improvement: Not Only TIS But All Companies Contribute to Profit
Profitability Improvement: Not Only TIS But All Companies Contribute to Profit Cardiac and Vascular: CV and Vascular are now back to growth trajectory CV: All shipping restrictions are lifted by FDA, and its related cost is largely reduced Vascular: Improve product portfolio mix and further pr
Slide 6: Capital Efficiency Improvement
Capital Efficiency Improvement Sale of Policy Shareholdings Sale of Olympus stocks (continue business alliance) The policy shareholding stocks are now less than 1% among the entire asset Implemented Share Buybacks Share buybacks of 44.2 BJPY at Olympus’s sale of Terumo stocks Optimal financing
Slide 7: Mid- to Long-term Vision
Mid- to Long-term Vision Trusted in medical settings as a Top Brand World-class overall Quality (products, supply, services) Global Corporation with Unique Excellence © Terumo Corporation 2016/5/10 7/12
Slide 8: Points to Achieve Mid- to Long-term Vision
Points to Achieve Mid- to Long-term Vision Strengthen Global Operations Accelerate Strategic Development Leverage Group’s Comprehensive Strength © Terumo Corporation 2016/5/10 8/12
Slide 9: Strengthen Global Operation: Production System
Strengthen Global Operation: Production System Europe: Advanced Tech Japan: Advanced Tech & New Idea US: Advanced Tech & New Idea Terumo Europe Vascutek Fujinomiya Ashitaka Yamaguchi Terumo Medical Clinical Supply Kofu TCVS Asia: Low cost mass production Terumo BCT Latin A: Low cost Terumo Vietnam T
Slide 10: Accelerate Strategic Development
Accelerate Strategic Development From pipeline development to creation of innovation for the growth over the next ten years Corporate Company R&D R&D Develop new businesses CTO Enhance product and technologies to HQs pipelines for business contribute to growth over companies the next ten years
Slide 11: Leverage Group's Comprehensive Strength
Leverage Group’s Comprehensive Strength Globalize corporate function and reinforce corporate governance Create synergy and promote collabo- Enhance global ration among each HR strategy business and region Enroot Corporate Mission and Vision throughout the group © Terumo Corporation 2016/5/10 11/12
Slide 12: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E-mail: [email protected] Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i